Mutation of MET D1228N as an Acquired Potential Mechanism of Crizotinib Resistance in NSCLC with MET Y1003H Mutation

被引：0

作者：

Zhu, Jinlian ^{[1
]}

Chen, Jie ^{[1
]}

Liu, Wei ^{[1
]}

Zhang, Junling ^{[2
]}

Gu, Yulan ^{[1
]}

机构：

[1] Nantong Univ, Dept Otolaryngol, Affiliated Changshu Hosp, Changshu, Jiangsu, Peoples R China

[2] 3D Med Inc, Med Dept, Shanghai, Peoples R China

来源：

LUNG CANCER-TARGETS AND THERAPY | 2024年 / 15卷

关键词：

MET Y1003H; MET D1228N; crizotinib; resistance; NSCLC; LUNG; CABOZANTINIB; SENSITIVITY; INHIBITORS; PATIENT; DOMAIN; SITE;

D O I：

10.2147/LCTT.S467584

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Mesenchymal-epithelial transition (MET) gene has been identified as a promising target for treatments. However, different sites of the MET mutation show different effects to MET inhibition. Here, we reported a non-small cell lung cancer (NSCLC) patient harboring MET Y1003H mutation who achieved a durable partial response to crizotinib with a PFS of 22.4 months. Furthermore, we report for the first time the identification of MET D1228N as a possible mechanism of acquired resistance to crizotinib in a patient with MET Y1003H mutation during disease progression.

引用

页码：123 / 128

页数：6

共 36 条

[1] Overcoming Acquired Resistance Mutation MET D1228N to Crizotinib With Cabozantinib in NSCLC With MET Exon 14 Skipping Mutation
Pruis, Melinda A.
Paats, M. S.
Geurts, W. R. R.
Dubbink, H. J.
Dingemans, A-M C.
JCO PRECISION ONCOLOGY, 2021, 5 : 849 - 853
[2] MET D1228N and D1246N are the Same Resistance Mutation in MET Exon 14 Skipping
Tsai, Jonathan M.
Hata, Aaron N.
Lennerz, Jochen K.
ONCOLOGIST, 2021, 26 (12): : E2297 - E2301
[3] Emergence of MET D1228N mutation as a resistance mechanism following an exceptional response to crizotinib in a MET-amplified triple-negative breast cancer patient
Parsons, Benjamin M.
Meier, David R.
Gurda, Grzegorz T.
Lofgren, Kristopher A.
Kenny, Paraic A.
CANCER RESEARCH, 2018, 78 (13)
[4] Acquisition of Cabozantinib-Sensitive MET D1228N Mutation During Progression on Crizotinib in MET-Amplified Triple-Negative Breast Cancer
Parsons, Benjamin M.
Meier, David R.
Richmond, Craig S.
Gurda, Grzegorz T.
Lofgren, Kristopher A.
Burkard, Mark E.
Deming, Dustin A.
Kenny, Paraic A.
CLINICAL BREAST CANCER, 2020, 20 (04) : E433 - E438
[5] Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 Skipping
Ignatius, Sai-Hong
Young, Lauren
Schrock, Alexa B.
Johnson, Adrienne
Klempner, Samuel J.
Zhu, Viola W.
Miller, Vincent A.
Ali, Siraj M.
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : 137 - 140
[6] Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report
Wang, Yu
Chen, Zheng
Han, Xiao
Li, Jiamei
Guo, Honglin
Shi, Junping
ONCOLOGIST, 2021, 26 (03): : 178 - 181
[7] Acquired EGFR Mutation as the Potential Resistance Driver to Crizotinib in a MET-Mutated Tumor
Benderra, Marc-Antoine
Aspeslagh, Sandrine
Postel-Vinay, Sophie
Bigot, Ludovic
De Baere, Thierry
Loriot, Yohann
Lacroix, Ludovic
Massard, Christophe
Vassal, Gilles
Andre, Fabrice
Soria, Jean-Charles
JOURNAL OF THORACIC ONCOLOGY, 2016, 11 (02) : E21 - E23
[8] Acquired Mechanism of Crizotinib Resistance in NSCLC with MET Exon 14 Skipping
Jin, Wei
Shan, Benjie
Liu, Hu
Zhou, Shoubing
Li, Wenjuan
Pan, Jing
Lin, Lin
Hu, Dandan
Pan, Yueyin
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (07) : E137 - E139
[9] CrizotinibDe novo acquisition of MET D1228N mutation in MET-amplified triple-negative breast cancer: case report
Reactions Weekly, 2018, 1718 (1) : 82 - 82
[10] Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET Amplification as Initial Resistance to Selpercatinib
Zhu, Viola W.
Zhang, Shannon S.
Zhang, Jian
Swensen, Jeffrey
Xiu, Joanne
Ou, Sai-Hong Ignatius
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (07) : E51 - E54

← 1 2 3 4 →